Christen Y, Waeber B, Nussberger J, Lee R J, Timmermans P B, Brunner H R
Hypertension Division, University Hospital, Lausanne, Switzerland.
Am J Hypertens. 1991 Apr;4(4 Pt 2):350S-353S. doi: 10.1093/ajh/4.4.350s.
We assessed the inhibitory effect of DuP 753, an orally active angiotensin II receptor antagonist, on the pressor action of exogenous angiotensin I and II in healthy volunteers. In a single dose study, doses of 2.5, 5, 10, 20, and 40 mg of DuP 753 or placebo were tested serially at one week intervals. In the multiple dose study, the administration of placebo or DuP 735 (5, 10, 20, or 40 mg, per os once daily) for eight consecutive days was evaluated. The blood pressure response to angiotensin I and II was inhibited in a dose-dependent fashion with a blocking effect still present 24 h post drug. DuP 753 also induced a dose-dependent compensatory rise in plasma renin. This new compound was well tolerated by these normal volunteers. Thus, DuP 753 appears to be a well tolerated, orally active, potent and long-lasting antagonist of angiotensin II in humans.
我们评估了口服活性血管紧张素II受体拮抗剂DuP 753对健康志愿者中外源性血管紧张素I和II升压作用的抑制效果。在单剂量研究中,2.5、5、10、20和40毫克的DuP 753或安慰剂剂量每隔一周依次进行测试。在多剂量研究中,评估了连续八天给予安慰剂或DuP 735(5、10、20或40毫克,口服,每日一次)的情况。对血管紧张素I和II的血压反应呈剂量依赖性抑制,用药后24小时仍有阻断作用。DuP 753还诱导血浆肾素呈剂量依赖性代偿性升高。这些正常志愿者对这种新化合物耐受性良好。因此,DuP 753似乎是一种在人体中耐受性良好、口服活性、强效且长效的血管紧张素II拮抗剂。